Literature DB >> 15353339

Soluble interleukin-2 receptor in cancer.

Saburo Murakami1.   

Abstract

Levels of serum sIL-2R (soluble interleukin-2 receptor) reflect the total amount of activated T lymphocytes in tumor infiltrating lymphocytes of cancer tissues and metastatic organs, because a part of alpha-chain of IL-2R is released into the bloodstream on the attachment of IL-2 (interleukin-2) to its specific IL-2R membrane. In most malignant diseases, elevated levels of serum sIL-2R are found, compare to normal control. Serum sIL-2R is a useful parameter for evaluating the disease stage and monitoring the disease progression during the post-treatment follow-up, though it is not an organ-specific parameter.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15353339     DOI： 10.2741/1461

Source DB:  PubMed          Journal:  Front Biosci        ISSN： 1093-4715


  17 in total

1.  Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Authors:  Yian Gu; Roy E Shore; Alan A Arslan; Karen L Koenig; Mengling Liu; Sherif Ibrahim; Anna E Lokshin; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2010-04-07       Impact factor: 2.506

2.  Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.

Authors:  Chen XiaoHong; Shen Bo; Xiang FangFang; Guo Man; Zou JianZhou; Liu ZhongHua; Lv WenLv; Cao XueSen; Ding XiaoQiang; Zhang Boheng
Journal:  Int J Clin Oncol       Date:  2019-06-10       Impact factor: 3.402

3.  Placenta-specific expression of the interleukin-2 (IL-2) receptor β subunit from an endogenous retroviral promoter.

Authors:  Carla J Cohen; Rita Rebollo; Sonja Babovic; Elizabeth L Dai; Wendy P Robinson; Dixie L Mager
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

4.  Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.

Authors:  Beverly J Lange; Richard K Yang; Jacek Gan; Jaquelyn A Hank; Eric L Sievers; Todd A Alonzo; Robert B Gerbing; Paul M Sondel
Journal:  Pediatr Blood Cancer       Date:  2011-06-16       Impact factor: 3.167

5.  Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Michelle K Manske; Thomas E Witzig; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

6.  Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004.

Authors:  Yuta Shibamoto; Minako Sumi; Shunsuke Onodera; Haruo Matsushita; Chikao Sugie; Yukihisa Tamaki; Hiroshi Onishi; Eisuke Abe; Masahiko Koizumi; Daisuke Miyawaki; Seiji Kubota; Etsuyo Ogo; Takuma Nomiya; Mitsuhiro Takemoto; Hideyuki Harada; Ippei Takahashi; Yoshio Ohmori; Naoya Ishibashi; Sunao Tokumaru; Kazunori Suzuki
Journal:  Int J Clin Oncol       Date:  2013-12-03       Impact factor: 3.402

7.  Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).

Authors:  Roniel Cabrera; Miguel Ararat; Mengde Cao; Yiling Xu; Clive Wasserfall; Mark A Atkinson; Chen Liu; David R Nelson
Journal:  Dig Dis Sci       Date:  2010-02       Impact factor: 3.199

Review 8.  High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.

Authors:  Yujian Zhang; Ira Pastan
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 9.  Immunology of hepatocellular carcinoma.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-08-18

10.  Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Authors:  Yujian Zhang; Laiman Xiang; Raffit Hassan; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.